Journal of Literature Pharmacy Sciences

Tırnak Mantarı Enfeksiyonu (Onikomikoz) ve Topikal Tedavide Yararlanımı Artırma Yöntemleri
Nail Fungal Infection (Onychomycosis) and the Methods of Increasing Usage in Topical Treatment
Esra KODANa, Ülker GÜLb, Figen TIRNAKSIZa
aGazi Üniversitesi Eczacılık Fakültesi, Farmasötik Teknoloji ABD, Ankara, TÜRKİYE
bSağlık Bilimleri Üniversitesi Tıp Fakültesi, Dermatoloji ABD, Ankara, TÜRKİYE
J Lit Pharm Sci. 2020;9(2):171-83
doi: 10.5336/pharmsci.2019-70802
Article Language: TR
Full Text
ÖZET
 Tırnak mantarı (onikomikoz), el-ayak tırnaklarını etkileyen ve tüm tırnak hastalıklarının yaklaşık %50'sini oluşturan bir mantar enfeksiyonudur. Genellikle dermatofitler, az bir kısmı da dermatofit olmayan küfler ve mayalar tarafından oluşturulmaktadır. Obezite, diyabet, HIV, sigara içme, yaşlılık ve immün yetmezlik gibi faktörler hastalığa yakalanma riskini artırmaktadır. Onikomikoz tedavisi, enfekte bölgeye ve hastalığın şiddetine göre belirlenmektedir. Tedavi seçenekleri oral, topikal ve bir cihazın da kullanıldığı tedaviler olarak sınıflandırılmaktadır. Oral tedavi, yan etki riskinin yüksek olması nedeni ile çoğunlukla topikal tedaviden sonra düşünülmektedir. Topikal tedavi, düşük yan etki olasılığı, sistemik ilaç etkileşimine yol açmaması ve hasta uyuncunun daha iyi olması açısından avantajlı görünmektedir. Fakat etken maddenin yoğun keratinize tırnağı geçmesi ve enfekte bölgeye penetrasyonu tedaviyi sınırlandırmaktadır. Topikal uygulamada karşılaşılan sıkıntıları giderebilmek, etken madde penetrasyonunu ve tedavinin etkinliğini artırmak için değişik fiziksel ve kimyasal yaklaşımlar geliştirilmiştir. Fiziksel yaklaşım; tırnak plağının aşındırılıp kalınlığının azaltılması, tırnak plağında µm boyutunda deliklerin açılması, iyontoforez ile penetrasyonun artırılması ve tırnağın hidrate edilerek geçirgenliğinin artırılması gibi yöntemleri içermektedir. Kimyasal yaklaşım ise tırnak plağının geçirgenliğinin artırılması amacıyla çeşitli penetrasyon artırıcıların kullanılmasına dayanmaktadır. Bu yaklaşımların yanı sıra bazı cihazlar da etken maddenin penetrasyonunu artırmak için tasarlanmıştır. Bu yaklaşımlar tek başına ya da birlikte kullanılarak topikal tedavinin etkinliğinin artırılıp süresinin azaltılması amaçlanmaktadır.

Anahtar Kelimeler: Onikomikoz; tırnak; tedavi; antifungal ajanlar; tırnağa penetrasyon
ABSTRACT
 Nail fungal (onychomycosis) is a fungal infection that affects hands and toenails and accounts for about 50% of all nail diseases. It is usually formed by dermatophytes, with a small proportion by non-dermatophytes yeasts and molds. Factors such as obesity, diabetes, HIV, smoking, old age and immunodeficiency increase risk of getting disease. Onychomycosis treatment is determined according to infected area and severity of the disease. Treatment options are classified as oral, topical and using a device. Oral treatment is usually considered after topical treatment because of the high risk of side effects. Topical treatment seems to be advantageous in terms of the possibility of low side effects, no systemic drug interaction and better patient compliance. However, penetration of the active substance through intense keratinized nail and penetration into infected area limit treatment. Various physical and chemical approaches have been developed to eliminate the problems encountered in topical application and increase the penetration of the active substance and effectiveness of the treatment. Physical approach; reduction of the thickness by etching of the nail plate, forming holes in size of µm on the nail plate, increasing penetration by iontophoresis and increasing permeability of the nail by hydrating. The chemical approach is based on the use of various penetration enhancers to increase the permeability of the nail plate. Additionally, some devices are designed to increase the penetration of the active substance. Using these approaches alone or in combination, it is aimed to increase the effectiveness and decrease the duration of topical treatment.

Keywords: Onychomycosis; nail; treatment; antifungal agents; nail penetration
REFERENCES:
  1. Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol. 2003;149(65):1-4. [Crossref]  [PubMed] 
  2. Matricciani L, Talbot K, Jones S. Safety and efficacy of tinea pedis and onychomycosis treatment in people with diabetes: a systematic review. J Foot Ankle Res. 2011;4(4):26. [Crossref]  [PubMed]  [PMC] 
  3. Zaias N. Onychomycosis. The Nail in Health and Disease. 2nd ed. New York: Spectrum Publications Inc; 1980. p.1-5. [Crossref] 
  4. Achten G, Parent D. The normal and pathologic nail. Int J Dermatol. 1983;22(10):556-65. [Crossref]  [PubMed] 
  5. Kobayashi Y, Miyamoto M, Sugibayashi K, Morimoto Y. Drug permeation through the three layers of the human nail plate. J Pharm Pharmacol. 1999;51(3):271-8. [Crossref]  [PubMed] 
  6. Lynch MH, O'Guin WM, Hardy C, Mak L, Sun TT. Acidic and basic hair/nail ("hard") keratins: their colocalization in upper cortical and cuticle cells of the human hair follicle and their relationship to "soft" keratins. J Cell Biol. 1986;103(6):2593-606. [Crossref]  [PubMed]  [PMC] 
  7. Forslind B. Biophysical studies of the normal nail. Acta Derm Venereol. 1970;50(3):161-8. [PubMed] 
  8. Murdan S. Enhancing the nail permeability of topically applied drugs. Expert Opin Drug Deliv. 2008;5(11):1267-82. [Crossref]  [PubMed] 
  9. Gupta AK, Jain HC, Lynde CW, Watteel GN, Summerbell RC. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada--a multicenter survey of 2001 patients. Int J Dermatol. 1997;36(10):783-7. [Crossref]  [PubMed] 
  10. Lubeck DP. Measuring health-related quality of life in onychomycosis. J Am Acad Dermatol. 1998;38(5):64-8. [Crossref]  [PubMed] 
  11. Niewerth M, Korting HC. Management of onychomycoses. Drugs. 1999;58(2):283-96. [Crossref]  [PubMed] 
  12. Baran R, Tosti A. Chemical avulsion with urea nail lacquer. J Dermatolog Treat. 2002;13(4):161-4. [Crossref]  [PubMed] 
  13. Repka MA, Mididoddi PK, Stodghill SP. Influence of human nail etching for the assessment of topical onychomycosis therapies. Int J Pharm. 2004;282(1-2):95-106. [Crossref]  [PubMed] 
  14. Gupta AK, Simpson FC. New therapeutic options for onychomycosis. Expert Opin Pharmacother. 2012;13(8):1131-42. [Crossref]  [PubMed] 
  15. Helou J, Maatouk I, Hajjar MA, Moutran R. Evaluation of Nd:YAG laser device efficacy on onychomycosis: a case series of 30 patients. Mycoses. 2016;59(1):7-11. [Crossref]  [PubMed] 
  16. Bonhert K, Dorizas A, Sadick NS. Efficacy of combination therapy with efinaconazole 10% solution and 1064 nm Nd:YAG laser for treatment of toenail onychomycosis. J Cosmet Laser Ther. 2019;21(3):179-83. [Crossref]  [PubMed] 
  17. Aspiroz C, Fortu-o Cebamanos B, Rezusta A, Paz-Cristóbal P, Domínguez-Luzón F, Gené Díaz J, et al. Photodynamic therapy for onychomycosis. Case report and review of the literature. Rev Iberoam Micol. 2011;28(4):191-3. [Crossref]  [PubMed] 
  18. Gurzadyan GG, Görner H, Schulte-Frohlinde D. Ultraviolet (193, 216 and 254 nm) photoinactivation of Escherichia coli strains with different repair deficiencies. Radiat Res. 1995;141(3):244-51. [Crossref]  [PubMed] 
  19. Dai T, Tegos GP, Rolz-Cruz G, Cumbie WE, Hamblin MR. Ultraviolet C inactivation of dermatophytes: implications for treatment of onychomycosis. Br J Dermatol. 2008;158(6):1239-46. [Crossref]  [PubMed]  [PMC] 
  20. Boker A, Rolz-Cruz G, Cumbie B, Kimball AB. A single-center, prospective, open-label, pilot study of the safety, local tolerability, and efficacy of ultraviolet-C (UVC) phototherapy for the treatment of great toenail onychomycosis. J Am Acad Dermatol. 2008;58(2 Suppl 2):AB82. [Crossref] 
  21. Cronin LJ, Mildren RP, Moffitt M, Lauto A, Morton CO, Stack CM, et al. An investigation into the inhibitory effect of ultraviolet radiation on Trichophyton rubrum. Lasers Med Sci. 2014;29(1):157-63. [Crossref]  [PubMed] 
  22. Lecha M, Effendy I, de Chauvin MF, Di Chiacchio N, Baran R; Taskforce on Onychomycosis Education. Treatment options--development of consensus guidelines. J Eur Acad Dermatol Venereol. 2005;19(Suppl 1):25-33. [Crossref]  [PubMed] 
  23. Iorizzo M, Piraccini BM, Rech G, Tosti A. Treatment of onychomycosis with oral antifungal agents. Expert Opin Drug Deliv. 2005;2(3):435-40. [Crossref]  [PubMed] 
  24. Lipner SR, Scher RK. Onychomycosis: treatment and prevention of recurrence. J Am Acad Dermatol. 2019;80(4):853-67. [Crossref]  [PubMed] 
  25. Marty JP. Amorolfine nail lacquer: a novel formulation. J Eur Acad Dermatol Venereol. 1995;4:17-21. [Crossref] 
  26. Mertin D, Lippold BC. In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: prediction of the penetration rate of antimycotics through the nail plate and their efficacy. J Pharm Pharmacol. 1997;49(9):866-72. [Crossref]  [PubMed] 
  27. Walters KA, Flynn GL, Marvel JR. Physicochemical characterization of the human nail: permeation pattern for water and the homologous alcohols and differences with respect to the stratum corneum. J Pharm Pharmacol. 1983;35(1):28-33. [Crossref]  [PubMed] 
  28. Marshall RC. Characterisation of the proteins of human hair and nail by electrophoresis. J Invest Dermatol. 1983;80(6):519-24. [Crossref]  [PubMed] 
  29. Mertin D, Lippold BC. In vitro permeability of the human nail and of a keratin membrane from bovine hooves: influence of the partition coefficient octanol/water and the water solubility of drugs on their permeability and maximum flux. J Pharm Pharmacol. 1997;49(1):30-4. [Crossref]  [PubMed] 
  30. Kobayashi Y, Komatsu T, Sumi M, Numajiri S, Miyamoto M, Kobayashi D, et al. In vitro permeation of several drugs through the human nail plate: relationship between physicochemical properties and nail permeability of drugs. Eur J Pharm Sci. 2004;21(4):471-7. [Crossref]  [PubMed] 
  31. Walters KA, Flynn GL, Marvel JR. Physicochemical characterization of the human nail: solvent effects on the permeation of homologous alcohols. J Pharm Pharmacol. 1985;37(11):771-5. [Crossref]  [PubMed] 
  32. Flores FC, Chiu WS, Beck RCR, da Silva CB, Delgado-Charro MB. Enhancement of tioconazole ungual delivery: combining nanocapsule formulation and nail poration approaches. Int J Pharm. 2018;15;535(1-2):237-44. [Crossref]  [PubMed] 
  33. Mahtab A, Anwar M, Mallick N, Naz Z, Jain GK, Ahmad FJ, et al. Transungual delivery of ketoconazole nanoemulgel for the effective management of onychomycosis. AAPS PharmSciTech. 2016;17(6):1477-90. [Crossref]  [PubMed] 
  34. Amra K, Momin M. Formulation evaluation of ketoconazole microemulsion-loaded hydrogel with nigella oil as a penetration enhancer. J Cosmet Dermatol. 2019;18(6):1742-50. [Crossref]  [PubMed] 
  35. Wróblewska M, Szekalska M, Hafner A, Winnicka K. Oleogels and bigels as topical drug carriers for ketoconazole- development and in vitro characterization. Acta Poloniae Pharmaceutica-Drug Research. 2018;75(3):777-86.
  36. Bseiso EA, Nasr M, Sammour OA, Abd El Gawad NA. Novel nail penetration enhancer containing vesicles "nPEVs" for treatment of onychomycosis. Drug Deliv. 2016;23(8):2813-9. [Crossref]  [PubMed] 
  37. Shah VH, Jobanputra A. Enhanced ungual permeation of terbinafine HCI delivered through liposome-loaded nail lacquer formulation optimized by QbD approach. AAPS PharmSciTech. 2018;19(1):213-24. [Crossref]  [PubMed] 
  38. Tanrıverdi ST, Özer Ö. Novel topical formulations of Terbinafine-HCl for treatment of onychomycosis. Eur J Pharm Sci. 2013;12;48(4-5):628-36. [Crossref]  [PubMed] 
  39. Tanrıverdi ST, Polat SH, Metin DY, Kandiloğlu G, Özer Ö. Terbinafine hydrochloride loaded liposome film formulation for treatment of onychomycosis: in vitro and in vivo evaluation. J Liposome Res. 2016;26(2):163-73. [Crossref]  [PubMed] 
  40. Rocha KAD, Krawczyk-Santos AP, Andrade LM, Souza LC, Marreto RN, Gratieri T, et al. Voriconazole-loaded nanostructured lipid carriers (NLC) for drug delivery in deeper regions of the nail plate. Int J Pharm. 2017;5;531(1):292-98. [Crossref]  [PubMed] 
  41. Hao J, Li SK. Transungual iontophoretic transport of polar neutral and positively charged model permeants: effects of electrophoresis and electroosmosis. J Pharm Sci. 2008;97(2):893-905. [Crossref]  [PubMed]  [PMC] 
  42. De Berker D, Mawhinney B, Sviland L. Quantification of regional matrix nail production. Br J Dermatol. 1996;134(6):1083-6. [Crossref]  [PubMed] 
  43. Kumar S, Kimball AB. New antifungal therapies for the treatment of onychomycosis. Expert Opin Investig Drugs. 2009;18(6):727-34. [Crossref]  [PubMed] 
  44. Murthy SN, Wiskirchen DE, Bowers CP. Iontophoretic drug delivery across human nail. J Pharm Sci. 2007;96(2):305-11. [Crossref]  [PubMed] 
  45. Di Chiacchio N, Kadunc BV, de Almeida AR, Madeira CL. Nail abrasion. J Cosmet Dermatol. 2003;2(3-4):150-2. [Crossref]  [PubMed] 
  46. Sumikawa M, Egawa T, Honda I, Yamamoto Y, Sumikawa Y, Kubota M, et al. Effects of foot care intervention including nail drilling combined with topical antifungal application in diabetic patients with onychomycosis. J Dermatol. 2007;34(7):456-64. [Crossref]  [PubMed] 
  47. Salter SA, Ciocon DH, Gowrishankar TR, Kimball AB. Controlled nail trephination for subungual hematoma. Am J Emerg Med. 2006;24(7):875-7. [Crossref]  [PubMed] 
  48. Ciocon D, Gowrishankar TR, Herndon T, Kimball AB. How low should you go: novel device for nail trephination. Dermatol Surg. 2006;32(6):828-33. [Crossref]  [PubMed] 
  49. Boker A, Ciocon D, Kimball A. A randomized, double-blind placebo-controlled, pilot study of 1% terbinafine cream applied twice daily and delivered via nail plate microporation for the treatment of subungual toenail onychomycosis. J Am Acad Dermatol. 2007;56(2 Suppl 2):AB114. [Crossref] 
  50. Díaz CD, Iglesias MEL, de Bengoa Vallejo RB, Diaz MC. Transungual delivery of ciclopirox is increased 3-4 fold by mechanical fenestration of human nail plate in an in vitro model. Pharmaceutics. 2019;11(1):29. [Crossref]  [PubMed]  [PMC] 
  51. Delgado-Charro MB. Iontophoretic drug delivery across the nail. Expert Opin Drug Deliv. 2012;9(1):91-103. [Crossref]  [PubMed] 
  52. Manda P, Sammeta SM, Repka MA, Murthy SN. Iontophoresis across the proximal nail fold to target drugs to the nail matrix. J Pharm Sci. 2012;101(7):2392-97. [Crossref]  [PubMed] 
  53. Nair AB, Kim HD, Chakraborty B, Singh J, Zaman M, Gupta A, et al. Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. J Pharm Sci. 2009;98(11):4130-40. [Crossref]  [PubMed] 
  54. Kushwaha A, Shivakumar HN, Murthy SN. Iontophoresis for drug delivery into the nail apparatus: exploring hyponychium as the site of delivery. Drug Dev Ind Pharm. 2016;42(10):1678-82. [Crossref]  [PubMed] 
  55. Gunt HB, Kasting GB. Effect of hydration on the permeation of ketoconazole through human nail plate in vitro. Eur J Pharm Sci. 2007;32(4-5):254-60. [Crossref]  [PubMed] 
  56. ?veikauskaitė I, Alius Pockevičius A, Briedis V. Potential of chemical and physical enhancers for transungual delivery of amorolfine hydrochloride. Materials.(Basel). 2019;12(7):1028. [Crossref]  [PubMed]  [PMC] 
  57. Gradisar H, Friedrich J, Krizaj I, Jerala R. Similarities and specificities of fungal keratinolytic proteases: comparison of keratinases of paecilomyces marquandii and doratomyces microsporus to some known proteases. Appl Environ Microbiol. 2005;71(7):3420-6. [Crossref]  [PubMed]  [PMC] 
  58. Chouhan P, Saini TR. Hydration of nail plate: A novel screening model for transungual drug permeation enhancers,International Journal of Pharmaceutics. 2012;436,1-2,179-82. [Crossref]  [PubMed] 
  59. Sun YS, Liu JC, Wang JCT, De Doncker P. Nail Penetration. Focus on topical delivery of antifungal drugs for onychomycosis treatment. In: Bronaugh RL, Maibach HI, eds. Percutaneous Absorption Drugs Cosmetics Mechanisms Methodology. 3rd ed. New York: Marcel Dekker Inc. 1999. p.759-87.
  60. Nair AB, Sammeta SM, Vaka SR, Murthy SN. A study on the effect of inorganic salts in transungual drug delivery of terbinafine. J Pharm Pharmacol. 2009;61(4):431-7. [Crossref]  [PubMed] 
  61. Nair AB, Chakraborty C, Murthy SN. Effect of polyethylene glycols on the trans-ungual delivery of terbinafine. Curr Drug Deliv. 2010;7(5):407-14. [Crossref]  [PubMed] 
  62. Gupta AK, Versteeg SG, Shear NH, Piguet V, Tosti A, Piraccini BM, et al. A practical guide to curing onychomycosis: how to maximize cure at the patient, organism, treatment, and environmental level. Am J Clin Dermatol. 2019;20(1):123-33. [Crossref]  [PubMed] 
  63. Täuber A, Müller-Goymann CC. Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model. Mol Pharm. 2014;7;11(7):1991-6. [Crossref]  [PubMed] 
  64. Kerai LV, Bardés J, Hilton S, Murdan S. Two strategies to enhance ungual drug permeation from UV-cured films: incomplete polymerisation to increase drug release and incorporation of chemical enhancers. Eur J Pharm Sci. 2018;123:217-27. [Crossref]  [PubMed] 
  65. Rotta I, Ziegelmann PK, Otuki MF, Riveros BS, Bernardo NL, Correr CJ, et al. Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments. JAMA Dermatol. 2013;149(3):341-9. [Crossref]  [PubMed] 
  66. Singal A, Pandhi D, Agrawal SK, Das S. Comparative efficacy of topical 1% butenafine and 1% clotrimazole in tinea cruris and tinea corporis: a randomized, double-blind trial. J Dermatolog Treat. 2005;16(5-6):331-5. [Crossref]  [PubMed] 
  67. Kumar KJR, Muralidharan S, Dhanaraj SA. Anti-fungal activity of microemulsion based fluconazole gel for onychomycoss against Aspergillus niger. Int J Pharm Sci. 2012;5(1):96-102.
  68. Gupta AK, Paquet M. Improved efficacy in onychomycosis therapy. Clin Dermatol. 2013;31(5):555-63. [Crossref]  [PubMed] 
  69. Van Hoogdalem EJ, Van den Hoven WE, Terpstra IJ, Van Zijtveld J, Verschoor JSC, Visser JN, et al. Nail penetration of the antifungal agent oxiconazole after repeated topical application in healthy volunteers, and the effect of acetylcysteine. Eur J Pharm Sci. 1997;5(3):119-27. [Crossref] 
  70. Elewski BE, Rich P, Pollak R, Pariser DM, Watanabe S, Senda H, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68(4):600-8. [Crossref]  [PubMed] 
  71. Pal P, Thakur RS, Ray S, Mazumder B. Design and development of a safer non-invasive transungual drug delivery system for topical treatment of onychomycosis. Drug Dev Ind Pharm. 2015;41(7):1095-9. [Crossref]  [PubMed] 
  72. Christensen L, Turner R, Weaver S, Caserta F, Long L, Ghannoum M, et al. Evaluation of the ability of a novel miconazole formulation to penetrate nail by using three in vitro nail models. Antimicrob Agents Chemother. 2017;61(7):e02554-16. [Crossref]  [PubMed]  [PMC] 
  73. ?veikauskaitė I, Briedis V. Effect of film-forming polymers on release of naftifine hydrochloride from nail lacquers. Int J Polym Sci. 2017:1-7. [Crossref] 
  74. Elewski BE, Aly R, Baldwin SL, González Soto RF, Rich P, Weisfeld M, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73(1):62-9. [Crossref]  [PubMed] 
  75. Akhtar N, Sharma H, Pathak K. Onychomycosis: potential of nail lacquers in transungual delivery of antifungals. Scientifica (Cairo). 2016;2016:1387936. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com